Genflow Biosciences Plc
GENF.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.05M
Close$
Share Statistics
| Market cap | $10.05 Million |
|---|---|
| Enterprise Value | $9.94 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 2.29 |
| Outstanding Shares | 469,141,420 |
Return
| Return on Equity | 257.37% |
|---|---|
| Return on Assets | -313.35% |
| Return on Invested Capital | 257.37% |
Valuation & Multiples
| P/E Ratio | -7.4 |
|---|---|
| PEG | 20.52 |
| Price to Sales | - |
| Price to Book Ratio | -1.78 |
| Enterprise Value to Revenue | 11.97 |
| Enterprise Value to EBIT | -7.01 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Genflow Biosciences Plc
5 employees
CEO: Eric Leire Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnol...